Spero Therapeutics
Edit info- Founded: 2013
- Location: Cambridge, MA
- Employee range: 50 - 200
- Clinical stage: Clin3
- Therapy area: UTI
- Drug types: INF
- Lead product: Tebipenem HBr
- Funding: $5.9M grant Jul 2019; $77M IPO Nov 2017
sperotherapeutics.com linkedin.com job board
Business:
Anti-infectives
Drug notes:
SPR720 Clin2 NTM infection; SPR206 Clin1 hospital bacterial infections
About:
Spero Therapeutics is developing a pipeline of therapies to treat bacterial infections. With the growing global threat of antibiotic resistance, innovative therapeutic approaches are needed to treat serious infections. Spero is delivering differentiated medicines to help patients suffering from serious rare orphan diseases and life threatening infections. This includes SPR720, an oral antibiotic designed to treat nontuberculous mycobacterial (NTM) pulmonary disease which is the first approved novel agent for NTM.
Jobs:
News:
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
crunchbase
Feb 28, 2024
Science/business updates
external-link
4 Analysts Have This to Say About Spero Therapeutics
crunchbase
Sep 5, 2023
Science/business updates
external-link
Yes
web
Jan 1, 2025
I'm happy to help, but I need a news title to classify. "Yes" is not a news title. Please provide a real news title, and I'll be happy to classify it for you.
external-link
Our President & CEO, Sath Shukla will attend H.C. Wainwright & Co., LLC Global Investment Conference September 9-11. We look forward to discussing the latest insights and sharing a corporate presentat
linkedin
Sep 23, 2024
Science/business updates
external-link
TD Cowen Upgrades Spero Therapeutics to Buy
crunchbase
Aug 6, 2024
Science/business updates
external-link
Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline - GlobeNewswire
googlenews
May 3, 2022
Science/business updates
external-link
Today we announced the publication of a paper in American Society for Microbiology's Antimicrobial Agents and Chemotherapy. The paper focuses on our Phase 1 #ClinicalTrial evaluating lung pharmacokine
linkedin
Oct 23, 2024
Science/business updates
external-link
Spero Therapeutics to Report Third Quarter 2024 Financial - GlobeNewswire
googlenews
Nov 7, 2024
Funding-related
external-link
👨👩👧👦 Happy #WorkingParentsDay! Today, we celebrate all the incredible #Sperobes who excel not only in their roles here at Spero but also in their most important role—being incredible parents. Your
linkedin
Sep 23, 2024
New hires
external-link
Spero Therapeutics to Participate in H.C. Wainwright Annual
crunchbase
May 16, 2024
Science/business updates
external-link
GSK pays $66M to rescue Spero's antibiotic after FDA ...
fiercebiotech.com
Dec 23, 2024
Funding-related
external-link
Spero Therapeutics: Strategic Shift and Earnings Update - TipRanks
googlenews
Nov 14, 2024
Science/business updates
external-link
Spero to cut 39% of workforce on failed study, stock plunges 20% (NASDAQ:SPRO) - Seeking Alpha
googlenews
Oct 29, 2024
Science/business updates
external-link
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
crunchbase
May 1, 2024
Funding-related
external-link
ALPMY: 3 Affordable Pharma Stocks to Buy for Portfolio Gains - StockNews.com
googlenews
Apr 12, 2024
Science/business updates
external-link
Spero Therapeutics Names Esther Rajavelu Chief Financial, Business Officer
crunchbase
Nov 1, 2023
New hires
external-link
Earnings call: Spero Therapeutics Q2 2024 update highlights pipeline progress
crunchbase
Aug 10, 2024
Science/business updates
external-link
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024 - GlobeNewswire
googlenews
Oct 16, 2024
Science/business updates
external-link
Spero Therapeutics says cash and cash equivalents as of December 31 were about $76.3M
crunchbase
Jan 5, 2024
Funding-related
external-link
Spero Therapeutics Inc. (SPRO) Quarterly 10-Q Report - Quartz
googlenews
Nov 14, 2024
Science/business updates
external-link
Spero Therapeutics (SPRO) Stock Increased 0.52%: Details
crunchbase
Nov 9, 2022
Science/business updates
external-link
Spero Therapeutics files $300M mixed securities shelf (NASDAQ:SPRO)
crunchbase
Mar 15, 2024
Funding-related
external-link
Spero Therapeutics Appoints Thomas Parr, Ph.D. as Chief ...
fiercebiotech.com
Dec 23, 2024
New hires
external-link
Spero Therapeutics Provides Corporate Update and 2024 Outlook - GlobeNewswire
googlenews
Jan 5, 2024
Science/business updates
external-link
Spero Therapeutics Receives Complete Response Letter from - GlobeNewswire
googlenews
Jun 27, 2022
Science/business updates
external-link
Spero Therapeutics Awarded up to an Additional $12.9 - GlobeNewswire
googlenews
Jan 19, 2022
Funding-related
external-link
Spero Therapeutics Enters Into a Non-Dilutive Revenue - GlobeNewswire
googlenews
Sep 30, 2021
Funding-related
external-link
There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding - Simply Wall St
googlenews
Nov 2, 2024
Funding-related
external-link
At this year's IDWeek Meeting, we are sharing a poster presentation highlighting in vitro resistance propensity data from SPR720, our candidate for the treatment of MAC #NTMPD. The poster will be pres
linkedin
Oct 23, 2024
Science/business updates
external-link
Spero Therapeutics (NASDAQ:SPRO) Lowered to In-Line Rating by Evercore ISI - MarketBeat
googlenews
Dec 20, 2024
Science/business updates
external-link
Spero Therapeutics Announces Positive Topline Results from - GlobeNewswire
googlenews
Sep 8, 2020
Science/business updates
external-link
Spero speared by antibiotic flop, triggering 39% workforce cut
crunchbase
Oct 30, 2024
Science/business updates
external-link
Spero Therapeutics stock hits 52-week low at $1.01 By Investing.com - Investing.com Australia
googlenews
Dec 19, 2024
Science/business updates
external-link
Cambridge biotech pulls plug on lung disease drug, cuts 39% of workforce - The Business Journals
googlenews
Oct 31, 2024
Science/business updates
external-link
Spero Therapeutics Restructures Focus on Key R&D Projects - TipRanks
googlenews
Oct 29, 2024
Science/business updates
external-link
💻 Happy #ITProfessionalsDay! A huge thank you to the IT experts like Sperobe Johnny S. who keep our systems running and our tech challenges solved. Your hard work powers our innovation every day.
linkedin
Sep 23, 2024
New hires
external-link
Thinking about buying stock in Hanryu Holdings, Absci Corp, Spero Therapeutics, BioXcel Therapeutics, or Cybin?
crunchbase
Nov 14, 2023
Funding-related
external-link
Spero to lay off 75% of workforce, change strategy after FDA challenges study results - BioPharma Dive
googlenews
May 4, 2022
Science/business updates
external-link
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript March 13, 2024
crunchbase
Mar 15, 2024
Science/business updates
external-link
Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
googlenews
Nov 17, 2024
Science/business updates
external-link
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
crunchbase
May 30, 2024
Science/business updates
external-link
Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer
crunchbase
Jun 14, 2023
New hires
external-link
Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
googlenews
Dec 16, 2024
Science/business updates
external-link
Penny Stocks To Buy With Just $1500: PMVP, BOLD, SPRO - 24/7 Wall St.
googlenews
Sep 27, 2024
Funding-related
external-link
Spero Therapeutics Reports Wider Q3 Loss, Revenue Falls 47% Amid Restructuring - StockTitan
googlenews
Nov 14, 2024
Science/business updates
external-link
Spero Therapeutics reports setback in SPR720 study - Investing.com
googlenews
Oct 29, 2024
Science/business updates
external-link
We are attending the IDWeek Meeting! We're excited to share insights on our unique approach targeting #InfectiousDisease & connect with fellow ID industry leaders.
Check out the event details here:
linkedin
Oct 23, 2024
Science/business updates
external-link
Spero Therapeutics stock hits 52-week low at $1.01 - Investing.com
googlenews
Dec 18, 2024
Science/business updates
external-link
Spero Therapeutics announces publication of SPR719 trial data
crunchbase
Oct 2, 2024
Science/business updates
external-link
Spero Therapeutics to Present at Upcoming September Investor Conferences
crunchbase
Sep 4, 2024
Funding-related
external-link
Dianthus Therapeutics, Inc. on LinkedIn: Today we reported our Q1 2024 financial results and highlighted recent…
crunchbase
May 9, 2024
Science/business updates
external-link
Wainwright reiterates Buy rating on Spero Therapeutics with PIVOT-PO enrolment on track - Investing.com
googlenews
Dec 2, 2024
Science/business updates
external-link
Evercore ISI Group Downgrades Spero Therapeutics (SPRO) - MSN
googlenews
Dec 20, 2024
Science/business updates
external-link
Spero Therapeutics files $300M mixed securities shelf
crunchbase
Mar 15, 2024
Funding-related
external-link
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections - GlobeNewswire
googlenews
Feb 28, 2024
Science/business updates
external-link
Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?
crunchbase
Mar 14, 2024
Funding-related
external-link
Spero Therapeutics (SPRO) Stock: Why It Surged Over 150% Today
crunchbase
Sep 23, 2022
Science/business updates
external-link
Shareholders in Spero Therapeutics (NASDAQ:SPRO) are in the red if they invested three years ago - Yahoo Finance
googlenews
May 10, 2024
Funding-related
external-link
Spero Formed to Develop First-in-Class Therapeutics for ...
fiercebiotech.com
Dec 23, 2024
Science/business updates
external-link
In Latin, “Spero” translates to “hope.”
At Spero Therapeutics, we are committed to advancing differentiated treatment approaches for #RareDiseases and multidrug-resistant bacterial infections. Hope i
linkedin
Oct 23, 2024
Science/business updates
external-link
Spero speared by antibiotic flop, triggering 39% workforce cut - Fierce Biotech
googlenews
Oct 30, 2024
Science/business updates
external-link
Leal Therapeutics raises $45M; SynOx adds to Series B - Endpoints News
googlenews
Oct 30, 2024
Funding-related
external-link
Today we announced our third quarter financial results. Read more in our press release: https://bit.ly/3YMgL5f
linkedin
Nov 23, 2024
Science/business updates
external-link
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update - StockTitan
googlenews
Oct 29, 2024
Science/business updates
external-link
Shareholders in Spero Therapeutics (NASDAQ:SPRO) are in the red if they invested three years ago
crunchbase
May 10, 2024
Funding-related
external-link
Spero Therapeutics Provides Corporate Update and 2024 Outlook
crunchbase
Jan 5, 2024
Science/business updates
external-link
Spero Therapeutics Announces Publication of SPR720 Phase 1 - GlobeNewswire
googlenews
Oct 2, 2024
Science/business updates
external-link
Spero Therapeutics to Lay Off 39% of Employees - BioSpace
googlenews
Oct 30, 2024
New hires
external-link
Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update - GlobeNewswire
googlenews
Nov 14, 2024
Science/business updates
external-link
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
crunchbase
Nov 1, 2023
New hires
external-link
GSK buys into Spero’s comeback plan - BioPharma Dive
googlenews
Sep 22, 2022
Funding-related
external-link
Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024 - StockTitan
googlenews
Nov 7, 2024
Science/business updates
external-link
TD Cowen cuts Spero Therapeutics shares to Hold, lacks clarity on catalyst timeline - Investing.com
googlenews
Nov 18, 2024
Science/business updates
external-link
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
googlenews
Oct 27, 2024
Funding-related
external-link
Spero nets $54M biodefense R&D contract for its lead ...
fiercebiotech.com
Dec 23, 2024
Funding-related
external-link
What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnings - Yahoo Finance
googlenews
Nov 13, 2024
Science/business updates
external-link
Sath Shukla, our President and Chief Executive Officer, is participating in a fireside chat and one-on-one meetings at the Cantor Fitzgerald Annual Global Healthcare Conference. More info here: https:
linkedin
Sep 23, 2024
Science/business updates
external-link
Biogen CMO Maha Radhakrishnan joins Sofinnova—Chutes & Ladders - Fierce Biotech
googlenews
Aug 9, 2024
New hires
external-link
Spero Therapeutics Dodges Investor Suit Over FDA Approval (1) - Bloomberg Law
googlenews
Oct 29, 2024
Science/business updates
external-link
Spero Therapeutics stock hits 52-week low at $1.03 By Investing.com - Investing.com UK
googlenews
Oct 30, 2024
Science/business updates
external-link
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update - GlobeNewswire
googlenews
Aug 5, 2024
Science/business updates
external-link
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update - GlobeNewswire
googlenews
Oct 29, 2024
Science/business updates
external-link
Spero Therapeutics reports Q1 EPS (24c), consensus (4c)
crunchbase
May 15, 2024
Science/business updates
external-link
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
crunchbase
Mar 15, 2024
Science/business updates
external-link
Happy Holidays from our team! We are thankful for all those who have supported us in our mission to advance potentially life-saving therapeutics.
linkedin
Dec 24, 2024
Science/business updates
external-link
Spero Therapeutics’ bacterial infection treatment gains FDA IND clearance
crunchbase
Feb 29, 2024
Science/business updates
external-link
SPRO: 3 Pharma Stocks to Buy Before Year-End
crunchbase
Jan 11, 2024
Science/business updates
external-link
Short Volatility Alert: Spero Therapeutics, Inc.
crunchbase
Sep 23, 2022
Science/business updates
external-link
GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr - GlobeNewswire
googlenews
Sep 22, 2022
Science/business updates
external-link
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
crunchbase
Jan 11, 2024
Science/business updates
external-link
Bad news from FDA prompts Spero to lay off 75% of staff, drop UTI drug - Fierce Biotech
googlenews
May 3, 2022
New hires
external-link
Insiders In Spero Therapeutics Left Out From 14% Price Rise After Disposing Stock
crunchbase
Nov 3, 2023
Funding-related
external-link
We are attending the CHEST 2024 Meeting in Boston from October 6-9. Our team is excited to connect with other industry leaders to gain valuable insights on the current challenges in clinical practice.
linkedin
Oct 23, 2024
Science/business updates
external-link
Glaxo, Atlas syndicate bankrolls Spero's drive into the clinic ...
fiercebiotech.com
Dec 23, 2024
Funding-related
external-link
What 4 Analyst Ratings Have To Say About Spero Therapeutics - Benzinga
googlenews
Dec 20, 2024
Science/business updates
external-link
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
crunchbase
Jul 3, 2024
Funding-related
external-link
© 2025 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com